Build Muscle With Peptides: GH Stack, Supplements & Biomarkers

The short version

Lean mass is the longevity asset most users underinvest in. After 30, sarcopenia takes ~3–5% of muscle per decade without intervention. The compounds and supplements on this page are the research-cited ones with the strongest signal for preserving and building lean tissue - but they only work in a body that is actually recovering. Sleep, protein, and the cofactors below are not optional.

Why this protocol works

Growth-hormone-axis peptides (tesamorelin, ipamorelin, CJC-1295, sermorelin) work by amplifying the body's natural GH pulses rather than supplying exogenous HGH. The published data shows IGF-1 elevation in the 30–80% range from baseline at therapeutic doses - clinically meaningful for body composition without the negative-feedback suppression of direct HGH use.

The supplements that matter are the cofactors GH receptors actually need: glycine for sleep-pulse magnitude, magnesium for receptor function, zinc for hormonal cofactor support, vitamin D for IGF-1 response. Skipping these is why many users see weak responses to GH peptides at otherwise reasonable doses.

The biomarkers are simpler than people make them. IGF-1 is the primary marker. Fasting glucose tells you whether your insulin sensitivity is holding (GH peptides can modestly affect this). DEXA every 6 months gives you the actual lean-mass-vs-fat-mass split that scale weight cannot.

Deep Dive

The physiology: muscle is built at the balance point of synthesis and breakdown

Skeletal muscle is not a static tissue. Roughly **1 to 2 percent of its protein is broken down and rebuilt every day**, which means visible hypertrophy is the slow accumulation of a favorable balance between **muscle protein synthesis (MPS)** and **muscle protein breakdown (MPB)**. Net growth only happens when MPS exceeds MPB, sustained across weeks and months. That is why a single hard workout or a single high-protein day changes almost nothing on its own.

Two independent signals drive MPS, and they converge on the same intracellular switch, **mTORC1**. The first is **mechanical tension** from resistance training. The second is **amino acid availability**, specifically the branched-chain amino acid **leucine**, which acts as the trigger telling the cell that enough substrate is present to build. Research on the leucine threshold suggests roughly **2.5 to 3 grams of leucine per meal** (about 20 to 40 grams of high-quality protein) is needed to maximally stimulate MPS. Beyond that, the "muscle full" effect kicks in: MPS peaks around 1.5 to 2 hours after a protein feeding and returns toward baseline within roughly 2 to 3 hours even while amino acids keep arriving. That single fact is why protein distributed across the day tends to outperform the same total eaten in one dose.

Sustained growth also depends on **satellite cells**, resident muscle stem cells that donate new nuclei so a fiber can support a larger volume. With age, muscle becomes less responsive to both leucine and training, a phenomenon called **anabolic resistance**, which is the physiology behind why older lifters generally need more protein and more mechanical stimulus to generate the same signal.

How GH-axis peptides work at the tissue level

The peptides on this page fall into two mechanistic classes that are often confused. **GHRH analogs** (sermorelin, tesamorelin, CJC-1295) bind the growth-hormone-releasing-hormone receptor on the pituitary. **Ghrelin mimetics**, also called growth-hormone secretagogues (ipamorelin and the oral compound MK-677), act on a different receptor, GHS-R, and also blunt somatostatin, the brake on GH release. Because the two classes push different levers, combining a GHRH analog with a ghrelin mimetic produces a **larger, synergistic GH pulse** than either alone, which is the physiological rationale behind the common CJC-1295 plus ipamorelin pairing.

All of these act upstream on the pituitary, so they work with the body's own pulsatility and feedback rather than around it. Downstream, GH drives both **hepatic IGF-1** (the endocrine signal measured in blood) and **local IGF-1 produced inside muscle**, which activates the PI3K/Akt/mTOR pathway and helps recruit satellite cells. The local, autocrine arm is a large part of why circulating IGF-1 is only a proxy for what is happening in the tissue itself.

Reading the biomarkers: what each number is really telling you

**IGF-1** is the workhorse marker not because it is the most anabolic molecule but because it is measurable in a way GH is not. GH is secreted in sharp pulses and cleared within minutes, so a random GH draw is nearly meaningless. IGF-1, carried in a ternary complex with **IGFBP-3** and an acid-labile subunit, has a half-life of roughly 12 to 16 hours and therefore reflects integrated GH exposure over about a day. Read it against an **age-adjusted reference range**, because normal IGF-1 falls steadily across the decades.

**Total and free testosterone** matter because testosterone, not GH, is the dominant hormonal driver of contractile hypertrophy. Only about **1 to 2 percent of total testosterone circulates free** and bioavailable; the rest is bound, largely to SHBG. A normal total paired with a low free value, common when SHBG is elevated, means the anabolic signal reaching muscle is weaker than the total alone would suggest. GH and IGF-1 are best understood as permissive here, with testosterone as the accelerator.

**Fasting glucose** is tracked because GH is a **counter-regulatory hormone**: it promotes lipolysis and induces mild peripheral insulin resistance. That physiology is why a rising fasting-glucose trend over time is a number worth watching and reviewing with a licensed clinician rather than ignoring. Finally, remember that **DEXA lean mass is not synonymous with contractile muscle**. It includes water, glycogen, and connective tissue, so it is worth pairing with an actual strength or performance measure before crediting a protocol.

What the research actually shows

The honest evidence base is more modest than marketing implies. The landmark systematic review by **Liu and colleagues in the Annals of Internal Medicine (2007)** pooled trials of growth hormone in healthy older adults and found lean body mass increased by about **2.1 kg** while fat mass fell by a similar amount, but there was **no measurable improvement in strength or functional capacity**, and adverse events (soft-tissue edema, joint pain, carpal-tunnel symptoms, glucose intolerance) were significantly more common. The most defensible interpretation is that much of the DEXA lean-mass gain from GH-axis elevation in non-deficient adults reflects fluid and connective tissue rather than new contractile protein.

It is also worth knowing that **tesamorelin's actual approved evidence** is for reducing visceral abdominal fat in HIV-associated lipodystrophy, not for building skeletal muscle. Realistically, IGF-1 shifts within weeks, but any genuine body-composition change sits on a **3 to 6 month horizon** and is dominated by training, protein, and sleep. Resistance training with adequate protein remains the only intervention with unambiguous hypertrophy evidence in healthy adults. Discuss any peptide protocol with a licensed clinician before starting.

The mistakes that quietly waste a protocol

- **Treating GH peptides as the primary muscle-building agent.** Mechanistically they are permissive cofactors; without progressive overload and sufficient protein there is nothing for the elevated IGF-1 to amplify. - **Chasing supraphysiologic IGF-1.** The receptor saturates, so pushing IGF-1 far above the age-adjusted range is associated with edema, joint pain, and insulin resistance rather than proportionally more muscle. - **Reading early lean-mass readings as pure muscle.** The first several pounds of "lean mass" on a scan are commonly water and glycogen, not contractile tissue, so even a DEXA number needs time and a performance check to interpret. - **Overlooking a weak testosterone axis.** When free testosterone is low, the anabolic accelerator is muted and GH-axis support has little to build on, a pattern worth reviewing with a clinician. - **Under-distributing protein.** Because of the muscle-full effect, three or four feedings that each clear the leucine threshold tend to outperform the same total protein concentrated into one or two meals.

Peptides commonly used for build muscle

Supplement stack pairing

Biomarkers to track for build muscle

The protocol

1. 1
   Baseline IGF-1 + fasting glucose + DEXA (or DEXA-equivalent body composition scan).
2. 2
   Start the lowest research-cited GH peptide dose. Higher doses do not produce proportionally bigger IGF-1 - the receptor saturates.
3. 3
   Resistance train 4x/week minimum. GH peptides without training amplify nothing.
4. 4
   Sleep 7+ hours. The biggest GH pulse of the day is in stage 3 sleep. Tesamorelin at 8pm with 5 hours of sleep wastes the protocol.
5. 5
   Re-test IGF-1 at week 6. Should be elevated 30–80% from baseline at therapeutic doses; if not, dose may be too low or sleep is suppressing the pulse.
6. 6
   DEXA every 12 weeks. Lean mass should be increasing; visceral fat should be decreasing.

Common pitfalls

• ×Dosing IGF-1 incorrectly - peak IGF-1 is 24–36h after a GH peptide dose. Drawing 12h after a dose underestimates the effect.
• ×Ignoring fasting glucose. GH peptides can modestly impair insulin sensitivity in some users. Catch it early with regular monitoring.
• ×Under-eating protein. The standard research threshold is ≥1.6g/kg for hypertrophy. Most users hitting that with GH peptides see meaningful body comp shift.
• ×Confusing scale weight with muscle gain. Water and glycogen alone can add 4–6 lbs in the first week of any new protocol. DEXA is the answer.

Frequently Asked Questions

Other goals